Search - tctmd.com

Displaying 741 - 760 of 7344

Sort: Relevancy | Date

News Daily News

Balancing Hypertension and Fall Risk: A Delicate Dance in Elderly Patients

L.A. McKeown

April 22, 2024

News Daily News

In Transporting Donor Hearts, SherpaPak Shows Promise Over Traditional Coolers

Yael L. Maxwell

April 18, 2024

News Daily News

New Heart Failure After AF Diagnosis Merits More Attention

Todd Neale

April 18, 2024

News Daily News

Diltiazem and DOAC Interaction Increases Bleeding Risk in AF

L.A. McKeown

April 18, 2024

News Daily News

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Michael O'Riordan

April 17, 2024

News Conference News ACC 2024

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

L.A. McKeown

April 16, 2024

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

News Conference News ACC 2024

Telemedicine Strategy After MI Scores a Win in TELE-ACS

Caitlin E. Cox

April 12, 2024

News Conference News ACC 2024

KARDIA-2: Zilebesiran Drops BP on Top of Common Antihypertensives

Shelley Wood

April 11, 2024

News Conference News ACC 2024

IVUS Benefits Patients Receiving DCBs for Fem-Pop Disease

Caitlin E. Cox

April 10, 2024

News Conference News ACC 2024

Need a Statin for Primary Prevention? There’s an App for That

Michael O'Riordan

April 10, 2024

News Conference News EHRA 2024

Preventive VT Ablation Before ICD Helps High-risk Ischemic Cardiomyopathy Patients

Todd Neale

April 10, 2024

News Conference News ACC 2024

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Yael L. Maxwell

April 09, 2024

News Conference News ACC 2024

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

L.A. McKeown

April 08, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

News Conference News EHRA 2024

Study Bolsters AF’s Link to Brain Infarcts, Cognitive Impairment

Todd Neale

April 08, 2024

Another Win for TAVI in Low-to-Intermediate Risk Patients

News Conference News ACC 2024

Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6

Yael L. Maxwell

April 08, 2024

News Conference News ACC 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Yael L. Maxwell

April 07, 2024

Presentation ACC 2024

Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy

Presenter: Eric Quinton Klug

April 07, 2024

News Conference News ACC 2024

SMART: Small Aortic Annuli May Fare Best With Self-Expandable Valve

L.A. McKeown

April 07, 2024

Advertisement

Balancing Hypertension and Fall Risk: A Delicate Dance in Elderly Patients

In Transporting Donor Hearts, SherpaPak Shows Promise Over Traditional Coolers

New Heart Failure After AF Diagnosis Merits More Attention

Diltiazem and DOAC Interaction Increases Bleeding Risk in AF

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Telemedicine Strategy After MI Scores a Win in TELE-ACS

KARDIA-2: Zilebesiran Drops BP on Top of Common Antihypertensives

IVUS Benefits Patients Receiving DCBs for Fem-Pop Disease

Need a Statin for Primary Prevention? There’s an App for That

Preventive VT Ablation Before ICD Helps High-risk Ischemic Cardiomyopathy Patients

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Study Bolsters AF’s Link to Brain Infarcts, Cognitive Impairment

Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy

SMART: Small Aortic Annuli May Fare Best With Self-Expandable Valve

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content